[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 22 of about 22
1. Tew WP, Kelsen DP, Ilson DH: Targeted therapies for esophageal cancer. Oncologist; 2005 Sep;10(8):590-601
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeted therapies for esophageal cancer.
  • Esophageal cancer is a highly aggressive neoplasm.
  • In 2005, 14,520 Americans will be diagnosed with esophageal cancer, and more than 90% will die of their disease.
  • On a global basis, cancer of the esophagus is the sixth leading cause of cancer death worldwide.
  • In fact, gastric and esophageal cancers together accounted for nearly 1.3 million new cases and 980,000 deaths worldwide in 2000-more than lung, breast, or colorectal cancer.
  • Although esophageal squamous cell carcinoma cases have steadily declined, the incidence of gastroesophageal junction adenocarcinoma has increased 4%-10% per year among U.S. men since 1976, more rapidly than for any other cancer type, and parallels rises in population trends in obesity and reflux disease.
  • With advances in surgical techniques and treatment, the prognosis of esophageal cancer has slowly improved over the past three decades.
  • (b) cancer detection at an advanced stage, with over 50% of patients with unresectable disease or distant metastasis at presentation;.
  • (c) high risk for recurrent disease after esophagectomy or definitive chemoradiotherapy;.
  • (d) unreliable noninvasive tools to measure complete response to chemoradiotherapy; and (e) limited survival achieved with palliative chemotherapy alone for patients with metastatic or unresectable disease.
  • Clearly, additional strategies are needed to detect esophageal cancer earlier and to improve our systemic treatment options.
  • Over the past decade, the field of drug development has been transformed with the identification of and ability to direct treatment at specific molecular targets.
  • This review focuses on novel targeted treatments in development for esophageal squamous cell carcinoma and distal esophageal and gastroesophageal junction adenocarcinoma.
  • [MeSH-major] Esophageal Neoplasms / therapy
  • [MeSH-minor] Antibodies, Monoclonal / pharmacology. Clinical Trials as Topic. Cyclooxygenase 2 Inhibitors / pharmacology. Humans. Neovascularization, Pathologic / drug therapy. Neovascularization, Pathologic / metabolism. Receptor Protein-Tyrosine Kinases / antagonists & inhibitors. Vascular Endothelial Growth Factor A / biosynthesis

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16177283.001).
  • [ISSN] 1083-7159
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Cyclooxygenase 2 Inhibitors; 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases
  • [Number-of-references] 128
  •  go-up   go-down


2. Higuchi K, Koizumi W, Tanabe S, Sasaki T, Katada C, Azuma M, Nakatani K, Ishido K, Naruke A, Ryu T: Current management of esophageal squamous-cell carcinoma in Japan and other countries. Gastrointest Cancer Res; 2009 Jul;3(4):153-61
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current management of esophageal squamous-cell carcinoma in Japan and other countries.
  • The incidence of adenocarcinoma of the distal esophagus or esophagogastric junction has increased considerably in Western countries during the past 3 decades, whereas the incidence of squamous-cell carcinoma has decreased slightly.
  • In Japan, most esophageal cancers are squamous-cell carcinomas.
  • Endoscopic examinations are more frequently performed in Japan for routine screening and diagnosis and treatment than in other countries, thereby increasing the detection rate of superficial esophageal carcinomas.
  • In Europe and North America, many clinical trials have been conducted to assess the effectiveness of neoadjuvant chemoradiotherapy followed by surgery in patients with resectable, advanced esophageal cancer.
  • In Japan, surgical resection had been the mainstay of treatment for esophageal cancer.
  • Since the results of the Japan Clinical Oncology Group (JCOG) 9907 study were reported, neoadjuvant chemotherapy with cisplatin plus 5-fluorouracil followed by surgery has emerged as a new standard treatment.
  • As for definitive chemoradiotherapy, cisplatin, 5-fluorouracil, and concurrent radiotherapy dosed to 50.4 Gy are used as standard treatment in a randomized clinical trial performed in North America.
  • In patients who have T4 tumors and/or M1 lymph-node metastasis, chemoradiotherapy with cisplatin and 5-fluorouracil is considered standard treatment, but docetaxel, cisplatin, and 5-fluorouracil plus concurrent radiotherapy is also being studied.
  • Controlled studies have not shown that palliative chemotherapy is superior to best supportive care, but cisplatin plus 5-fluorouracil is still considered standard therapy.
  • It is hoped that targeted agents will be effective for esophageal cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Onkologie. 2005 Dec;28(12):647-50 [16330888.001]
  • [Cites] Semin Oncol. 1999 Oct;26(5 Suppl 15):2-8 [10566604.001]
  • [Cites] Clin Gastroenterol Hepatol. 2005 Jul;3(7 Suppl 1):S67-70 [16013002.001]
  • [Cites] Gastrointest Endosc. 2005 Jul;62(1):31-6 [15990816.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2310-7 [15800321.001]
  • [Cites] Jpn J Clin Oncol. 2004 Oct;34(10):615-9 [15591460.001]
  • [Cites] J Clin Oncol. 1999 Oct;17(10):3270-5 [10506629.001]
  • [Cites] JAMA. 1999 May 5;281(17):1623-7 [10235156.001]
  • [Cites] N Engl J Med. 1999 Mar 18;340(11):825-31 [10080844.001]
  • [Cites] Eur J Surg. 1998 Nov;164(11):849-57 [9845131.001]
  • [Cites] Cancer. 1998 Nov 15;83(10):2049-53 [9827707.001]
  • [Cites] J Clin Oncol. 1998 May;16(5):1826-34 [9586897.001]
  • [Cites] Eur J Cancer. 1997 Jul;33(8):1216-20 [9301445.001]
  • [Cites] J Thorac Cardiovasc Surg. 1997 Aug;114(2):210-7 [9270638.001]
  • [Cites] N Engl J Med. 1997 Jul 17;337(3):161-7 [9219702.001]
  • [Cites] J Clin Oncol. 1996 Jan;14(1):164-70 [8558192.001]
  • [Cites] Ann Oncol. 2002 May;13(5):721-9 [12075740.001]
  • [Cites] Hepatogastroenterology. 1994 Aug;41(4):391-3 [7959579.001]
  • [Cites] Cancer. 1994 Apr 1;73(7):1779-84 [8137201.001]
  • [Cites] Radiother Oncol. 1993 Jul;28(1):27-30 [7694321.001]
  • [Cites] World J Surg. 1992 Nov-Dec;16(6):1104-9; discussion 1110 [1455880.001]
  • [Cites] Jpn J Clin Oncol. 1992 Jun;22(3):172-6 [1518165.001]
  • [Cites] Jpn J Clin Oncol. 1991 Jun;21(3):176-9 [1942548.001]
  • [Cites] Cancer Treat Rep. 1983 Jul-Aug;67(7-8):713-5 [6683591.001]
  • [Cites] Cancer. 1980 Nov 15;46(10):2149-53 [7427858.001]
  • [Cites] Cancer Treat Rep. 1979 Nov-Dec;63(11-12):2019-21 [526935.001]
  • [Cites] Am J Gastroenterol. 2004 Jul;99(7):1226-32 [15233658.001]
  • [Cites] Ann Oncol. 2004 Jun;15(6):955-9 [15151954.001]
  • [Cites] Ann Oncol. 2004 Jun;15(6):947-54 [15151953.001]
  • [Cites] Gastrointest Endosc. 2004 Feb;59(2):199-204 [14745392.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4592-6 [14673047.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2697-702 [12860946.001]
  • [Cites] Jpn J Clin Oncol. 2003 Mar;33(3):111-21 [12672787.001]
  • [Cites] Med Oncol. 2003;20(1):19-24 [12665680.001]
  • [Cites] Gastrointest Endosc. 2003 Feb;57(2):165-9 [12556777.001]
  • [Cites] Eur J Cancer. 2009 Mar;45(5):756-64 [19128954.001]
  • [Cites] Clin Gastroenterol Hepatol. 2009 Feb;7(2):149-55 [19032991.001]
  • [Cites] Am J Gastroenterol. 2008 Jun;103(6):1340-5 [18510606.001]
  • [Cites] Radiother Oncol. 2008 Jun;87(3):398-404 [18405987.001]
  • [Cites] Gastrointest Endosc. 2008 May;67(6):814-20 [18371965.001]
  • [Cites] Cancer Chemother Pharmacol. 2008 Jun;62(1):77-84 [17762932.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Feb 1;70(2):391-5 [17980508.001]
  • [Cites] Br J Surg. 2007 Sep;94(9):1059-66 [17657720.001]
  • [Cites] Endoscopy. 2007 Sep;39(9):779-83 [17703385.001]
  • [Cites] J Nippon Med Sch. 2007 Apr;74(2):163-7 [17507793.001]
  • [Cites] Eur J Cancer. 2007 May;43(7):1188-99 [17383866.001]
  • [Cites] J Clin Oncol. 2007 Apr 1;25(10):1160-8 [17401004.001]
  • [Cites] Lancet Oncol. 2007 Mar;8(3):226-34 [17329193.001]
  • [Cites] Endoscopy. 2007 Jan;39(1):36-40 [17252458.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 Jun;4(6):688-94 [16713746.001]
  • [Cites] J Clin Oncol. 2006 Apr 1;24(10):1612-9 [16575012.001]
  • [Cites] N Engl J Med. 2006 Feb 9;354(6):567-78 [16467544.001]
  • [Cites] J Clin Oncol. 2002 Mar 1;20(5):1167-74 [11870157.001]
  • [Cites] Jpn J Clin Oncol. 2001 Sep;31(9):419-23 [11689594.001]
  • [Cites] Cancer. 2001 Jun 1;91(11):2165-74 [11391598.001]
  • [Cites] Ann Surg. 2000 Aug;232(2):225-32 [10903602.001]
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2915-21 [10561371.001]
  • [Cites] Br J Cancer. 2005 Nov 14;93(10):1112-6 [16278660.001]
  • (PMID = 19742141.001).
  • [ISSN] 1934-7820
  • [Journal-full-title] Gastrointestinal cancer research : GCR
  • [ISO-abbreviation] Gastrointest Cancer Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2739640
  •  go-up   go-down


3. Sivula A, Buskens CJ, van Rees BP, Haglund C, Offerhaus GJ, van Lanschot JJ, Ristimäki A: Prognostic role of cyclooxygenase-2 in neoadjuvant-treated patients with squamous cell carcinoma of the esophagus. Int J Cancer; 2005 Oct 10;116(6):903-8
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic role of cyclooxygenase-2 in neoadjuvant-treated patients with squamous cell carcinoma of the esophagus.
  • Based on our previous demonstration that elevated cyclooxygenase-2 (COX-2) expression is a prognostic factor for reduced survival in patients with adenocarcinoma of the esophagus, the aim of our study was to analyze the role of COX-2 expression in esophageal squamous cell carcinoma.
  • Eighty-one patients had not received any therapy before surgery whereas 36 patients received neoadjuvant chemotherapy as part of a randomized controlled trial.
  • In the patients who received no chemotherapy, COX-2 expression was low in 75% and high in 25% of the specimens.
  • In this patient group, high COX-2 expression associated with distal location of the tumor (p = 0.02), but did not correlate with any other clinicopathological parameter tested, including overall survival.
  • In the patient group who received neoadjuvant chemotherapy, postoperative COX-2 expression was low in 69% and high in 31%.
  • Our results show that the prognostic significance of COX-2 depends on the histological type of esophageal carcinoma and preoperative treatment of the patient.
  • In conclusion, COX-2 is not a prognostic marker in squamous cell carcinoma of the esophagus, but low COX-2 expression is associated with poor prognosis in the neoadjuvant-treated patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Esophageal Neoplasms / drug therapy. Prostaglandin-Endoperoxide Synthases / analysis
  • [MeSH-minor] Biomarkers, Tumor / analysis. Cyclooxygenase 2. Female. Gastrectomy. History, 17th Century. Humans. Male. Membrane Proteins. Neoadjuvant Therapy. Neoplasm Invasiveness. Neoplasm Metastasis. Prognosis. Survival Analysis

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15856454.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Historical Article; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Membrane Proteins; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human; EC 1.14.99.1 / Prostaglandin-Endoperoxide Synthases
  •  go-up   go-down


Advertisement
4. Steele NP, Tokayer A, Smith RV: Retrograde endoscopic balloon dilation of chemotherapy- and radiation-induced esophageal stenosis under direct visualization. Am J Otolaryngol; 2007 Mar-Apr;28(2):98-102
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retrograde endoscopic balloon dilation of chemotherapy- and radiation-induced esophageal stenosis under direct visualization.
  • INTRODUCTION: Esophageal stricture is a common complication following combined chemotherapy and radiation for advanced oropharyngeal cancer and severely compromises patients' quality of life.
  • The severity of the stenosis after concomitant therapy, combined with the proximal location of these strictures, renders standard bougienage techniques difficult, and the risk of perforation significant.
  • METHODS: Seven patients with advanced head and neck cancer treated with combined chemotherapy and radiation developed severe dysphagia requiring intervention for near total, or total, upper esophageal stenosis.
  • In this technique, a flexible endoscope is advanced in a retrograde fashion through the patient's gastrostomy site to the distal edge of the stenotic segment.
  • This procedure is performed under conscious sedation in an ambulatory setting.
  • RESULTS: The first patient in the series developed a pneumothorax during attempted passage of the guidewire in a retrograde fashion.
  • CONCLUSIONS: A retrograde endoscopic progressive balloon dilation for esophageal dilation under direct visualization provides palliation of swallowing difficulties in patients whose stenoses are not amenable to traditional techniques.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Catheterization / methods. Esophageal Stenosis / therapy. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Deglutition Disorders / etiology. Deglutition Disorders / therapy. Female. Humans. Male. Middle Aged. Radiotherapy / adverse effects. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17362814.001).
  • [ISSN] 0196-0709
  • [Journal-full-title] American journal of otolaryngology
  • [ISO-abbreviation] Am J Otolaryngol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


5. von Rahden BH, Stein HJ, Reiter R, Becker I, Siewert JR: Delayed aortic rupture after radiochemotherapy and esophagectomy for esophageal cancer. Dis Esophagus; 2003;16(4):346-9
MedlinePlus Health Information. consumer health - Radiation Therapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Delayed aortic rupture after radiochemotherapy and esophagectomy for esophageal cancer.
  • Spontaneous rupture of major vessels is a known though rare complication in treatment of patients with esophageal cancer, but its pathophysiology is not very well understood.
  • Because of a locally advanced squamous cell carcinoma of the distal esophagus, which was considered irresectable at the time of presentation, the patient had received one course of chemotherapy followed by synchronous chemoradiation (60 Gy, 5-fluorouracil and cisplatin) prior to surgery.

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14641303.001).
  • [ISSN] 1120-8694
  • [Journal-full-title] Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  • [ISO-abbreviation] Dis. Esophagus
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


6. Dominitz JA, Maynard C, Billingsley KG, Boyko EJ: Race, treatment, and survival of veterans with cancer of the distal esophagus and gastric cardia. Med Care; 2002 Jan;40(1 Suppl):I14-26
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Race, treatment, and survival of veterans with cancer of the distal esophagus and gastric cardia.
  • CONTEXT: Prior studies have found racial differences in the use of invasive procedures and in cancer survival.
  • OBJECTIVE: To assess the influence of race on the treatment and survival of patients with distal esophageal cancer.
  • PATIENTS: One thousand two hundred ninety white and 231 black male veterans with a new diagnosis of distal esophageal cancer during 1993 to 1997.
  • MAIN OUTCOME MEASURES: Utilization of surgical resection, chemotherapy, radiation therapy, and survival.
  • RESULTS: Black patients with esophageal adenocarcinoma were less likely to undergo surgery (OR, 0.54; 95% CI, 0.30-0.96) but had similar odds of undergoing chemotherapy and radiation therapy.
  • Black patients with squamous cell carcinoma (SCC) were less likely to undergo surgical resection (OR, 0.45; 95% CI, 0.29-0.70), but were more likely to undergo radiation therapy (OR, 1.72; 95% CI, 1.21-2.47) and chemotherapy (OR, 1.74; 95% CI, 1.19-2.54).
  • CONCLUSIONS: Black veterans with distal SCC are less likely than white veterans to undergo surgical resection, whereas the use of radiation therapy and chemotherapy, as well as mortality, is increased.
  • Black patients with distal esophageal adenocarcinoma have lower odds of undergoing surgical resection but have similar utilization of radiation therapy and chemotherapy and similar survival.
  • Despite the presence of an equal access medical system, treatment and outcomes differ for black and white veterans with distal esophageal cancer.
  • [MeSH-major] African Americans / statistics & numerical data. Esophageal Neoplasms / mortality. Esophageal Neoplasms / therapy. European Continental Ancestry Group / statistics & numerical data. Health Services Accessibility / statistics & numerical data. Hospitals, Veterans / utilization. Veterans / statistics & numerical data
  • [MeSH-minor] Adenocarcinoma / ethnology. Adenocarcinoma / mortality. Adenocarcinoma / therapy. Carcinoma, Squamous Cell / ethnology. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / therapy. Cardia / pathology. Chemotherapy, Adjuvant / utilization. Cohort Studies. Esophagectomy / utilization. Esophagogastric Junction / pathology. Health Services Research. Humans. Male. Proportional Hazards Models. Radiotherapy, Adjuvant / utilization. Retrospective Studies. Survival Analysis. United States / epidemiology

  • MedlinePlus Health Information. consumer health - African American Health.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11789626.001).
  • [ISSN] 0025-7079
  • [Journal-full-title] Medical care
  • [ISO-abbreviation] Med Care
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


7. Suto R, Enjoji A, Okudaira S, Furui J, Matsuo T, Kanematsu T: A second primary esophageal cancer developing 7 years after chemoradiotherapy for advanced esophageal cancer. J Gastroenterol; 2001 Jul;36(7):495-9
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A second primary esophageal cancer developing 7 years after chemoradiotherapy for advanced esophageal cancer.
  • We report a rare case of advanced carcinoma and a second primary carcinoma of the esophagus, both of which were successfully cured by chemotherapy and operation at different times.
  • In 1991, a 38-year-old Japanese man was diagnosed with advanced esophageal cancer, which was unresectable because of the bronchial invasion of the tumor.
  • He was given chemotherapy with cisplatin (CDDP), combined with radiotherapy.
  • In 1995, esophagoscopy demonstrated a lugol-unstained region located 3 cm distal from the area of radiation to the primary lesion shown by esophagography.
  • Nevertheless, yearly surveillance by endoscopy and histological examinations showed that the mucosa of the esophagus gradually began to demonstrate mild dysplasia, followed by severe dysplasia; in 1998, a diagnosis of squamous cell carcinoma was made.
  • Microscopic examination revealed that there had been pathologic complete response for the original advanced esophageal cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / therapy. Esophageal Neoplasms / diagnosis. Esophageal Neoplasms / therapy. Esophagectomy. Neoplasms, Second Primary / diagnosis. Neoplasms, Second Primary / therapy
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Humans. Male. Radiotherapy, Adjuvant

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11480795.001).
  • [ISSN] 0944-1174
  • [Journal-full-title] Journal of gastroenterology
  • [ISO-abbreviation] J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


8. Litle VR, Luketich JD, Christie NA, Buenaventura PO, Alvelo-Rivera M, McCaughan JS, Nguyen NT, Fernando HC: Photodynamic therapy as palliation for esophageal cancer: experience in 215 patients. Ann Thorac Surg; 2003 Nov;76(5):1687-92; discussion 1692-3
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy as palliation for esophageal cancer: experience in 215 patients.
  • BACKGROUND: Photodynamic therapy (PDT) utilizes a photosensitizing agent, light, and oxygen to endoscopically ablate cancer cells.
  • This review summarizes our experience with PDT for the palliation of bleeding or obstructing esophageal cancer (EC).
  • After Photofrin II injection, nonthermal light treatment was delivered endoscopically.
  • Dysphagia scores, duration of palliation, reinterventions, complications, and survival after treatment were reviewed.
  • Tumor histology included 179 adenocarcinomas, 33 squamous cell carcinomas, and 3 undifferentiated.
  • Seventy-five percent of EC were in the distal esophagus.
  • PDT complications included perforation (2% of treatment courses), stricture (2%), Candida esophagitis (2%), pleural effusions (4%), and sunburn (6%).
  • The procedure-related mortality rate was 1.8%, and median survival was 4.8 months.
  • CONCLUSIONS: PDT offers effective palliation for patients with obstructing EC in 85% of treatment courses.
  • The ideal EC patient for PDT palliation has an obstructing endoluminal cancer.
  • Patients living more than 2 months may require reintervention to maintain palliation of malignant dysphagia, and a multimodality treatment approach is common.
  • [MeSH-major] Dihematoporphyrin Ether / administration & dosage. Esophageal Neoplasms / drug therapy. Esophageal Neoplasms / mortality. Palliative Care / methods. Photochemotherapy / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cohort Studies. Esophagoscopy / methods. Female. Humans. Injections, Intralesional. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Risk Assessment. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14602313.001).
  • [ISSN] 0003-4975
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 97067-70-4 / Dihematoporphyrin Ether
  •  go-up   go-down


9. Kleinberg L, Knisely JP, Heitmiller R, Zahurak M, Salem R, Burtness B, Heath EI, Forastiere AA: Mature survival results with preoperative cisplatin, protracted infusion 5-fluorouracil, and 44-Gy radiotherapy for esophageal cancer. Int J Radiat Oncol Biol Phys; 2003 Jun 1;56(2):328-34
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mature survival results with preoperative cisplatin, protracted infusion 5-fluorouracil, and 44-Gy radiotherapy for esophageal cancer.
  • PURPOSE: To assess the long-term survival results after cisplatin, protracted infusion 5-fluorouracil, and concurrent radiotherapy (RT) followed by surgical resection of esophageal cancer.
  • METHODS AND MATERIALS: Ninety-two patients with esophageal cancer (65 with adenocarcinoma and 27 with squamous cell carcinoma) were treated in two sequential protocols of preoperative chemoradiotherapy.
  • The patients had tumor confined to the esophagus and regional nodes, including celiac nodes for middle and distal lesions.
  • In trial A (1989-1994), 50 patients were treated with 44 Gy RT (2 Gy/d) along with concurrent 5-fluorouracil 300 mg/m(2)/d given by protracted venous infusion on Days 1-30 and cisplatin 26 mg/m(2) on Days 1-5 and 26-30.
  • In trial B (1995-1997, 42 patients), the chemotherapy dosages during RT were reduced to 5-fluorouracil 225 mg/m(2)/d protracted venous infusion and cisplatin 20 mg/m(2)/d on Days 1-5 and 16-30; three cycles of paclitaxel 135 mg/m(2)and cisplatin 75 mg/m(2) were given postoperatively.
  • Surgery generally occurred 4-6 weeks after completion of the planned preoperative therapy.
  • RESULTS: Of the 92 patients, 86 (93%) underwent surgery (1 refused, 2 died preoperatively, and 3 developed evidence of metastatic disease).
  • Eight patients with pathologic Stage I tumor at the time of surgery had survival similar to those with a complete response to preoperative therapy.
  • The median survival for patients with pathologic Stage IIA, IIB, III, and IV disease at the time of surgery was 22, 13.5, 18, and 4.9 months, respectively.
  • No differences were noted in survival or response rate between those with adenocarcinoma or squamous cell carcinoma.
  • CONCLUSION: The promising 5-year survival results and low rate of late cancer-related deaths suggest that these regimens of intensive neoadjuvant therapy may improve the overall cure rate.
  • The pathologic stage after neoadjuvant therapy is an important predictor of survival and may be useful in selecting patients for novel adjuvant therapies.
  • Isolated local failure is uncommon, indicating that efforts to improve the therapeutic outcome should focus on optimizing systemic therapy rather than intensifying the RT.
  • Additional randomized data are needed to assess the benefits of this therapeutic approach fully.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Esophageal Neoplasms / drug therapy. Esophageal Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Combined Modality Therapy. Esophagectomy. Female. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Proportional Hazards Models. Survival Rate

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12738305.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


10. Hartwig W, Strobel O, Lordick F, Büchler MW, Werner J: [Multimodal therapy of esophageal cancer]. Z Gastroenterol; 2008 Oct;46(10):1207-13
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Multimodal therapy of esophageal cancer].
  • [Transliterated title] Multimodale Therapie des Osophaguskarzinoms.
  • Surgery is still the treatment of choice in patients with resectable oesophageal cancer.
  • However, recent randomised controlled trials suggest beneficial effects of adjuvant or neoadjuvant treatment modalities on progression-free and overall survival compared to surgery alone.
  • Neoadjuvant chemoradiotherapy in combination with surgery is most effective in squamous cell carcinomas.
  • In adenocarcinomas of the gastro-oesophageal junction neoadjuvant chemotherapy shows beneficial effects compared to surgery alone.
  • A transhiatal resection should be preferred in distal oesophageal cancer compared to a transthoracic oesophageal resection if the patient is in poor condition.
  • In all other cases a transthoracic resection remains the procedure of choice.
  • Chemoradiotherapy alone is an alternative to surgery in high-risk patients with squamous cell carcinomas of the oesophagus.
  • Therefore the treatment of patients with oesophageal cancer should always include an individualised, multimodal approach including surgery, chemotherapy, and radiotherapy.
  • [MeSH-major] Chemotherapy, Adjuvant / trends. Clinical Trials as Topic / trends. Digestive System Surgical Procedures / trends. Esophageal Neoplasms / therapy. Radiotherapy, Adjuvant / trends
  • [MeSH-minor] Combined Modality Therapy. Humans

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Clinical Trials.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Z Gastroenterol. 2008 Nov;46(11):1335. Hartung, W [corrected to Hartwig, W]
  • (PMID = 18937192.001).
  • [ISSN] 0044-2771
  • [Journal-full-title] Zeitschrift für Gastroenterologie
  • [ISO-abbreviation] Z Gastroenterol
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 39
  •  go-up   go-down


11. Sanyal S, Kaman L, Sinha SK: Splenic metastasis from esophageal cancer: report of a case. Surg Today; 2005;35(11):988-90
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Splenic metastasis from esophageal cancer: report of a case.
  • The spleen is an unusual site of metastasis from an esophageal malignancy.
  • We herein report the case of a 25-year-old woman who underwent a transhiatal esophagectomy and adjuvant radiotherapy and chemotherapy for squamous cell carcinoma of the lower third of the esophagus with pN1 lymph node metastasis.
  • A splenectomy, distal pancreatectomy, and resection of the splenic flexure with colocolic anastomosis were performed.
  • A histological examination of the resected specimen showed squamous cell carcinoma.
  • [MeSH-major] Carcinoma, Squamous Cell / secondary. Esophageal Neoplasms / pathology. Splenic Neoplasms / secondary

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Pathol. 1963 Jul;40:58-66 [13933237.001]
  • [Cites] World J Surg. 1985 Jun;9(3):468-76 [4040300.001]
  • [Cites] Surg Today. 1994;24(5):410-4 [8054811.001]
  • [Cites] Hepatogastroenterology. 2003 Sep-Oct;50(53):1336-7 [14571731.001]
  • [Cites] Cancer. 1987 Jul 1;60(1):100-2 [3581023.001]
  • [Cites] Arch Pathol Lab Med. 2000 Apr;124(4):526-30 [10747308.001]
  • [Cites] Eur J Cardiothorac Surg. 2002 Dec;22(6):1011-3 [12467831.001]
  • (PMID = 16249859.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


12. Chand M, Thomas RJ, Dabbas N, Bateman AC, Royle GT: Soft Tissue Metastases as the First Clinical Manifestation of Squamous Cell Carcinoma of the Esophagus: Case Report. World J Oncol; 2010 Jun;1(3):135-137

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Soft Tissue Metastases as the First Clinical Manifestation of Squamous Cell Carcinoma of the Esophagus: Case Report.
  • Soft tissue metastases are an uncommon presenting feature for primary solid tumours.
  • This case highlights a rare presentation in which a soft tissue mass is the first clinical manifestation of a widespread disseminated malignancy of the esophagus.
  • Core biopsies revealed squamous carcinoma.
  • Computed tomography scanning showed widespread metastatic disease, including lung, liver, kidney, omentum, subcutaneous and intramuscular lesions.
  • The distal esophagus was noted to be circumferentially thickened.
  • The patient remains well awaiting esophageal stenting and palliative chemotherapy.
  • In conclusion, it is important to be able to distinguish the origin of a soft-tissue swelling as the management will depend significantly on the histological type.
  • Soft-tissue metastases are rarely encountered as a presenting sign of an occult cancer.
  • Primary cancers that most commonly metastasise to soft tissues include those arising within the lung, colon and kidney.
  • This case demonstrates the utility of biopsy in the investigation of soft tissue masses when the clinical presentation is unusual.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Plast Surg. 1993 Oct;31(4):377-8 [8239441.001]
  • [Cites] Clin Orthop Relat Res. 1993 Nov;(296):213-7 [8222429.001]
  • [Cites] Br J Surg. 1970 Jul;57(7):529-30 [5427475.001]
  • [Cites] Cancer. 2008 Jan 1;112(1):193-203 [18040999.001]
  • [Cites] Ann Surg Oncol. 2000 Aug;7(7):526-34 [10947022.001]
  • [Cites] J Clin Oncol. 2007 Aug 20;25(24):3780-3 [17704428.001]
  • [Cites] Skeletal Radiol. 2000 May;29(5):270-4 [10883446.001]
  • [Cites] Eur J Surg Oncol. 2007 May;33(4):508-11 [17081724.001]
  • [Cites] Ann Thorac Surg. 1996 May;61(5):1525-6 [8633975.001]
  • (PMID = 29147193.001).
  • [ISSN] 1920-454X
  • [Journal-full-title] World journal of oncology
  • [ISO-abbreviation] World J Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Keywords] NOTNLM ; Biopsy / Esophagus / Occult cancer / Soft tissue metastasis / Squamous cell carcinoma
  •  go-up   go-down


13. González Ortiz DI, Toro DH: Esophageal cancer subtypes and survival rates at the VA Caribbean Healthcare System: a 10-year experience. Bol Asoc Med P R; 2009 Jul-Sep;101(3):14-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Esophageal cancer subtypes and survival rates at the VA Caribbean Healthcare System: a 10-year experience.
  • BACKGROUND: The incidence of the two main subtypes of esophageal cancer has changed in Western countries in the past two decades, where an increasing trend is observed for adenocarcinoma.
  • Up to date, there are no recent published data regarding esophageal cancer subtypes in Puerto Rico or its relationship with social habits.
  • MATERIALS/METHODS: A total of 169 records from our patients with esophageal cancer for a 10 year period were reviewed.
  • RESULTS: Two thirds (66%) of the patients had squamous cell carcinoma (SCC), with 47% located at the upper third, 40% in the middle third and 13% in the distal third of the esophagus.
  • Thirty four percent of the patients had a diagnosis of adenocarcinoma, mostly found in the distal third of the esophagus (71%), outnumbering those cases of squamous cell carcinoma found in the same area.
  • Most of the patients who received chemotherapy and radiotherapy had a diagnosis of squamous cell carcinoma, while those who had surgery were mostly adenocarcinoma cases.
  • At the time of diagnosis, about half of the patients with either type of cancer had metastatic disease.
  • According to the data collected, only 10 out of the 169 patients remained alive at the time of this record review, most of them with squamous cell carcinoma and after receiving chemotherapy and radiotherapy.
  • Regarding treatment with a proton pump inhibitor, H2 blocker or both, 66.3% of the patients with squamous cell carcinoma received those therapies, in contrast to only 33.7% of patients with adenocarcinoma.
  • CONCLUSIONS: There is an increasing trend for the frequency of adenocarcinoma compared to squamous cell carcinoma, which is comparable to the observed worldwide trend.
  • [MeSH-major] Adenocarcinoma / epidemiology. Carcinoma, Squamous Cell / epidemiology. Esophageal Neoplasms / epidemiology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Alcohol Drinking / epidemiology. Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Drug Utilization. Esophagectomy / utilization. Histamine H2 Antagonists / therapeutic use. Humans. Incidence. Male. Middle Aged. Morbidity / trends. Proton Pump Inhibitors / therapeutic use. Puerto Rico / epidemiology. Radiotherapy / utilization. Retrospective Studies. Smoking / epidemiology. Survival Rate

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20120980.001).
  • [ISSN] 0004-4849
  • [Journal-full-title] Boletín de la Asociación Médica de Puerto Rico
  • [ISO-abbreviation] Bol Asoc Med P R
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Puerto Rico
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Histamine H2 Antagonists; 0 / Proton Pump Inhibitors
  •  go-up   go-down


14. Fu JH, Rong TH, Li XD, Ma GW, Hu Y, Min HQ: [Cox regression analysis of the prognostic factors of unresectable esophageal carcinoma after stenting]. Ai Zheng; 2003 Jan;22(1):91-4
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cox regression analysis of the prognostic factors of unresectable esophageal carcinoma after stenting].
  • BACKGROUND & OBJECTIVE: There are many factors affect the prognosis of the patients with unresectable esophageal carcinoma who underwent intubation, however, it is unclear which ones are main causes so far.
  • This study was designed to analyze the prognostic factors of unresectable esophageal carcinoma after stenting in order to find the reasonable modalities of palliative therapy.
  • METHODS: Consecutive 102 patients with unresectable esophageal carcinoma who were eligible for inclusion criteria were analyzed after stenting.
  • Twelve factors including gender, age tumor site, tumor length, stricture degree in diameter, pathologic type, grade of cell differentiation, clinical tumor stage (T, N, M), pre-stenting therapy and post-stenting therapy (radiotherapy and/or chemotherapy) were used for Cox regression model analysis.
  • The results of Cox regression showed that invasion degree of primary tumor (T, P = 0.0410) and distal metastasis (M, P = 0.006) were the statistically significant prognostic factors.
  • There was no statistical significance in the survival of the patients affected by radiotherapy and/or chemotherapy after intubation.
  • CONCLUSION: T stage and M stage are the major prognostic factors affecting the survival of patients with unresectable esophageal carcinoma after stenting.
  • There is no benefit for survival of patients treated with radiotherapy and/or chemotherapy after intubation.
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Esophageal Neoplasms / therapy. Stents

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12561445.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


15. Leung SF, Griffith JF, Ahuja A, Chan AC: Influence of staging thoracic computed tomography on radiation therapy planning for esophageal carcinoma. J Thorac Imaging; 2002 Apr;17(2):145-50
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Influence of staging thoracic computed tomography on radiation therapy planning for esophageal carcinoma.
  • Radiation therapy with concurrent chemotherapy is frequently used as definitive treatment for esophageal carcinoma.
  • Although thoracic computed tomography (CT) is widely used in staging esophageal carcinoma, its application to radiation therapy planning has been regarded as optional rather than mandatory.
  • Conventional radiation therapy planning is esophagogram-based rather than CT-based.
  • The treatment port is generated by adding 5 cm to the proximal and distal margins of the tumor-involved segment as seen on esophagogram performed in the treatment position.
  • Historically, a maximum port length of 15 cm was recommended to avoid excessive treatment morbidity.
  • The authors examined the limitations of such a planning protocol by projecting conventional treatment ports onto the thoracic CT of 75 consecutive newly diagnosed cases of nondisseminated esophageal squamous cell carcinoma.
  • Thoracic CT should be a mandatory rather than optional imaging investigation in guiding radiation therapy planning for esophageal cancer.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiotherapy. Esophageal Neoplasms / pathology. Esophageal Neoplasms / radiotherapy. Neoplasm Staging. Radiography, Thoracic. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11956364.001).
  • [ISSN] 0883-5993
  • [Journal-full-title] Journal of thoracic imaging
  • [ISO-abbreviation] J Thorac Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Burstow M, Kelly T, Panchani S, Khan IM, Meek D, Memon B, Memon MA: Outcome of palliative esophageal stenting for malignant dysphagia: a retrospective analysis. Dis Esophagus; 2009;22(6):519-25
MedlinePlus Health Information. consumer health - Swallowing Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of palliative esophageal stenting for malignant dysphagia: a retrospective analysis.
  • Greater than 50% of patients with esophageal carcinoma are found to be incurable at the time of diagnosis, leaving only palliative options.
  • Self-expanding metal stents (SEMs) are effective for relieving symptoms and complications associated with esophageal carcinoma and improving quality of life.
  • We undertook a retrospective analysis to evaluate the experience of palliative esophageal stenting for symptomatic malignant dysphagia in our institution over a period of 7 years.
  • A number of variables including age, sex, presenting complaints, type of stent, indications of stenting, success or failure of stent insertion, survival rate, and complication rate were analyzed.
  • Tumors were confined to the distal esophagus and esophagogastric junction in 73 patients (81%), and the mid-esophagus in 17 (19%).
  • Adenocarcinoma was identified in 61 patients (67.8%) and squamous cell carcinoma in 29 (32.2%).
  • The mean survival time was 92.5 (0-638) days and median survival time was 61 days.
  • Those patients receiving adjuvant chemotherapy or radiotherapy survived significantly longer than those receiving stenting alone (152.8 days vs. 71.8 days).
  • There is no significant difference in complications or survival when using endoscopic or radiologic methods to deploy SEMs in patients with inoperable esophageal cancer.
  • Patients receiving adjuvant chemotherapy or radiotherapy, in addition to stenting, survived significantly longer than those with a stent only.

  • Genetic Alliance. consumer health - Dysphagia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19302213.001).
  • [ISSN] 1442-2050
  • [Journal-full-title] Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  • [ISO-abbreviation] Dis. Esophagus
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Takada J, Okuda K, Tani C, Kenno S, Oguro S, Shimokuni T, Aoki T, Nagaoka Y, Uno Y, Hamada H: [Complete recovery obtained with combined S-1 + CDDP therapy in a patient with multiple lung metastases from esophageal cancer]. Gan To Kagaku Ryoho; 2007 Nov;34(12):1967-9
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Complete recovery obtained with combined S-1 + CDDP therapy in a patient with multiple lung metastases from esophageal cancer].
  • PURPOSE: There are numerous reports on the subject of effectiveness in radio-chemotherapy with regard to esophageal cancer, suggesting especially the combination therapy of 5-FU + CDDP aimed for recovery.
  • Treatment becomes difficult when distal metastases appear during an adjuvant therapy followed by surgery.
  • Our report here is a case in which a complete recovery was obtained after changing to S-1, a prodrug of 5-FU, in response to multiple lung metastases which appeared during the combined 5-FU + CDDP therapy followed by surgery for esophageal cancer.
  • Endoscopy during a physical examination showed a Type 1 tumor 27-30 cm from the anterior teeth.
  • Detailed tests provided a preoperative diagnosis of esophageal cancer: Ut Type 1, T2-T3, N2, MO, IMO.
  • Pathological findings showed well-differentiated squamous cell carcinoma, pT1b (sm), pN1 (106-rec R), pStage II.
  • After completing the chemotherapy, CT revealed the resolution of the lung metastases and complete recovery was diagnosed.
  • Following this, a treatment with S-1 alone was continued until the appearance of bone metastases at which time radiotherapy was performed.
  • The treatment is currently ongoing and no recurrence of the lung metastases has been shown.
  • CONCLUSION: There have been numerous reports of the combination of S-1 + CDDP in esophageal cancer for NAC or in inoperable cases.
  • However, our report suggests that this method may be effective in cases of recurrence or distal metastases.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / therapeutic use. Esophageal Neoplasms / drug therapy. Esophageal Neoplasms / pathology. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Oxonic Acid / therapeutic use. Tegafur / therapeutic use
  • [MeSH-minor] Aged. Drug Combinations. Follow-Up Studies. Humans. Male. Prognosis. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18219867.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


18. Zacherl J, Sendler A, Stein HJ, Ott K, Feith M, Jakesz R, Siewert JR, Fink U: Current status of neoadjuvant therapy for adenocarcinoma of the distal esophagus. World J Surg; 2003 Sep;27(9):1067-74
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current status of neoadjuvant therapy for adenocarcinoma of the distal esophagus.
  • Prospective studies dealing with preoperative therapy in adenocarcinoma of the esophagus alone are rare.
  • The interpretation of the preferential phase II trials and a few phase III trials is complicated, as most studies include adenocarcinoma of the esophagus (i.e., Barrett's carcinoma), adenocarcinoma of the esophagogastric junction (including cardia carcinoma and subcardia carcinoma), or squamous cell carcinoma.
  • Preoperative chemotherapy, generally well tolerated, cannot decrease the incidence of local failure beyond the level achieved with surgery alone, but it might delay systemic relapse.
  • Generally, survival was ameliorated in patients responding to neoadjuvant treatment.
  • The prediction of responding patients to neoadjuvant therapy as well as the early identification of patients who will not respond is of utmost clinical importance.
  • Today, there is no absolute evidence that neoadjuvant treatment for patients with potentially resectable Barrett's cancer prolongs survival.
  • In patients with locally advanced, presumably not completely resectable adenocarcinoma of the esophagus, preoperative treatment appears to increase the chance for a curative resection and enhance survival in responding patients.
  • Neoadjuvant treatment of adenocarcinoma of the esophagus, as a consequence, is currently not the standard treatment and should be performed only within controlled clinical trials.
  • [MeSH-major] Adenocarcinoma / therapy. Barrett Esophagus / therapy. Esophageal Neoplasms / therapy. Neoadjuvant Therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 1993 Oct;218(4):571-6; discussion 576-8 [8215648.001]
  • [Cites] N Engl J Med. 1996 Aug 15;335(7):462-7 [8672151.001]
  • [Cites] Ann Thorac Surg. 1995 May;59(5):1085-90; discussion 1090-1 [7733702.001]
  • [Cites] Ann Thorac Surg. 1999 Dec;68(6):2021-4; discussion 2024-5 [10616970.001]
  • [Cites] Chirurg. 2000 Dec;71(12):1447-57 [11195063.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Dec 1;42(5):929-34 [9869212.001]
  • [Cites] Oncology (Williston Park). 1997 Sep;11(9 Suppl 9):63-7 [9330411.001]
  • [Cites] J Clin Oncol. 1993 Jun;11(6):1118-23 [8501498.001]
  • [Cites] Am J Gastroenterol. 1999 Apr;94(4):906-12 [10201455.001]
  • [Cites] Eur J Cancer. 1995;31A(5):665-70 [7640036.001]
  • [Cites] J Clin Oncol. 2001 Jun 15;19(12 ):3058-65 [11408502.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):455-62 [10653860.001]
  • [Cites] Mod Pathol. 1999 Mar;12(3):251-6 [10102609.001]
  • [Cites] Cancer. 1998 Nov 1;83(9):1908-16 [9806648.001]
  • [Cites] J Clin Oncol. 1993 Jan;11(1):22-8 [8418237.001]
  • [Cites] J Thorac Cardiovasc Surg. 1988 Aug;96(2):242-8 [2456424.001]
  • [Cites] Cancer. 1991 Aug 1;68(3):489-92 [2065268.001]
  • [Cites] Cancer. 1992 Jan 15;69(2):285-91 [1728358.001]
  • [Cites] Gastrointest Endosc. 1998 Aug;48(2):158-63 [9717781.001]
  • [Cites] Am J Clin Oncol. 1994 Feb;17(1):14-8 [8311001.001]
  • [Cites] Endoscopy. 1994 Nov;26(9):769-71 [7712984.001]
  • [Cites] Am J Clin Oncol. 1997 Feb;20(1):11-5 [9020280.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):305-13 [11208820.001]
  • [Cites] Anticancer Res. 1995 Sep-Oct;15(5B):2357-61 [8572652.001]
  • [Cites] Lancet. 2002 May 18;359(9319):1727-33 [12049861.001]
  • [Cites] Ann Surg Oncol. 1994 Jan;1(1):5-10 [7834428.001]
  • [Cites] Dis Esophagus. 2002;15(2):121-4 [12220418.001]
  • [Cites] Eur J Cardiothorac Surg. 1997 May;11(5):828-37 [9196296.001]
  • [Cites] Surg Clin North Am. 2000 Apr;80(2):659-82; discussions 683-6 [10836011.001]
  • [Cites] J Clin Oncol. 1996 Jan;14(1):156-63 [8558191.001]
  • [Cites] Br J Surg. 1998 Nov;85(11):1457-9 [9823902.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):283-5 [11208816.001]
  • [Cites] J Thorac Cardiovasc Surg. 1992 May;103(5):887-93; discussion 893-5 [1569771.001]
  • [Cites] Ann Thorac Surg. 1994 Dec;58(6):1574-8; discussion 1578-9 [7979718.001]
  • [Cites] Surgery. 1995 Nov;118(5):845-55 [7482272.001]
  • [Cites] Semin Surg Oncol. 1999 Sep;17 (2):125-31 [10449684.001]
  • [Cites] Ann Oncol. 1994;5 Suppl 3:17-26 [8204527.001]
  • [Cites] Cancer Detect Prev. 1996;20(1):63-7 [8907205.001]
  • [Cites] Cancer. 1996 May 15;77(10):1978-85 [8640659.001]
  • [Cites] Semin Oncol. 1997 Dec;24(6 Suppl 19):S19-89-S19-92 [9427275.001]
  • [Cites] Ann Surg. 2001 Mar;233(3):300-9 [11224616.001]
  • [Cites] N Engl J Med. 1998 Dec 31;339(27):1979-84 [9869669.001]
  • [Cites] N Engl J Med. 1996 Aug 15;335(7):509-10 [8672157.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1231-8 [2358838.001]
  • (PMID = 12934159.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 55
  •  go-up   go-down


19. Ajani JA, Komaki R, Putnam JB, Walsh G, Nesbitt J, Pisters PW, Lynch PM, Vaporciyan A, Smythe R, Lahoti S, Raijman I, Swisher S, Martin FD, Roth JA: A three-step strategy of induction chemotherapy then chemoradiation followed by surgery in patients with potentially resectable carcinoma of the esophagus or gastroesophageal junction. Cancer; 2001 Jul 15;92(2):279-86
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A three-step strategy of induction chemotherapy then chemoradiation followed by surgery in patients with potentially resectable carcinoma of the esophagus or gastroesophageal junction.
  • Preoperative chemotherapy or chemoradiotherapy has not improved the outcome for these patients.
  • Our study was designed to assess the feasibility of preoperative induction combination chemotherapy in addition to chemoradiotherapy to improve the curative resection rate, local control, and survival.
  • PATIENTS AND METHODS Patients having histologic proof of localized carcinoma (either squamous cell carcinoma or adenocarcinoma) of the esophagus or gastroesophageal junction underwent full classification including endoscopic ultrasonography (EUS).
  • Patients first received up to two courses of induction chemotherapy consisting of 5-fluorouracil at 750 mg/m(2)/day as continuous infusion on Days 1--5, cisplatin at 15 mg/m(2)/day as an intravenous bolus on Days 1--5, and paclitaxel at 200 mg/m(2) as a 24-hour intravenous infusion on Day 1.
  • Adenocarcinoma and distal esophageal location of carcinoma were observed frequently.
  • CONCLUSIONS: These data show that the three-step strategy of preoperative paclitaxel-based induction chemotherapy then chemoradiotherapy followed by surgery is feasible and appears quite active in patients having locoregional carcinoma of the esophagus or gastroesophageal junction.
  • Future investigations should focus on substituting cisplatin with less toxic agents and including more systemic therapy with newer classes of agents.
  • [MeSH-major] Adenocarcinoma. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell. Esophageal Neoplasms. Esophagogastric Junction / pathology. Stomach Neoplasms
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Combined Modality Therapy. Female. Fluorouracil / administration & dosage. Humans. Infusions, Intravenous. Injections, Intravenous. Male. Middle Aged. Neoadjuvant Therapy. Neoplasm Recurrence, Local. Paclitaxel / administration & dosage. Preoperative Care. Prognosis. Survival Analysis

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 American Cancer Society.
  • (PMID = 11466680.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


20. Schnirer II, Komaki R, Yao JC, Swisher S, Putnam J, Pisters PW, Roth JA, Ajani JA: Pilot study of concurrent 5-fluorouracil/paclitaxel plus radiotherapy in patients with carcinoma of the esophagus and gastroesophageal junction. Am J Clin Oncol; 2001 Feb;24(1):91-5
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Preoperative concurrent chemotherapy and radiotherapy can be highly effective but are often associated with significant rates of morbidity and even mortality.
  • Chemotherapy consisted of continuous infusion of 5-FU (300 mg/m2/d) for 5 days a week for 5 weeks, plus paclitaxel (45 mg/m2) given during 3 hours every week for 5 weeks.
  • Based on the tumor location and its resectability, the total dose of concurrent radiation varied between 45 Gy and 50.4 Gy.
  • One had GE junction cancer, six had distal esophageal cancer, and three had midesophageal cancer.
  • None of the patients was hospitalized during chemoradiation; all patients completed treatment as outpatients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Esophageal Neoplasms / drug therapy. Esophageal Neoplasms / radiotherapy. Esophagogastric Junction
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Aged. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Combined Modality Therapy. Drug Administration Schedule. Female. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Paclitaxel / administration & dosage. Pilot Projects. Radiation-Sensitizing Agents / administration & dosage. Radiotherapy / adverse effects

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11232959.001).
  • [ISSN] 0277-3732
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiation-Sensitizing Agents; P88XT4IS4D / Paclitaxel; U3P01618RT / Fluorouracil
  •  go-up   go-down


21. Swisher SG, Pisters PW, Komaki R, Lahoti S, Ajani JA: Gastroesophageal junction adenocarcinoma. Curr Treat Options Oncol; 2000 Dec;1(5):387-98
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The incidence rate of adenocarcinoma of the esophagogastric junction (AEG) is increasing in association with the epidemiologic rise in distal esophageal adenocarcinoma and gastric cardial (AEG type III) tumors.
  • The overall survival rate is poor in most patients with AEG because lymph node or visceral metastases are frequently present at the time patients become symptomatic.
  • Ablative treatments for early stage AEG, including endoscopic fulguration by cautery and laser or photodynamic therapy, are investigational at this time.
  • Locoregionally advanced AEG (T3, T4, N1, or M1a ) without distant systemic metastases (M1b) has a poor overall survival rate with surgery alone or definitive chemotherapy and radiation therapy without surgery.
  • Analysis of the use of multimodality treatment strategies for locoregionally advanced AEG types I and II have demonstrated improved survival rates in two small phase III trials with preoperative concurrent chemoradiotherapy followed by surgical resection.
  • In contrast, three small phase III trials with preoperative concurrent or sequential chemoradiotherapy in patients with predominantly squamous cell carcinoma did not demonstrate any clear survival advantage.
  • Additionally, a randomized phase III study evaluating preoperative chemotherapy without radiation therapy in esophageal cancer (predominantly adenocarcinoma) has demonstrated no survival benefit.
  • At the present time, preoperative chemoradiotherapy remains investigational.
  • For locoregionally advanced gastric adenocarcinoma, including AEG type III, postoperative concurrent 5-fluorouracil (5-FU)-based chemoradiotherapy is associated with improved survival as demonstrated in a recently completed random assignment trial (INT 0116).
  • As a result, surgery with postoperative chemoradiotherapy has recently become the standard of care for patients with AJCC stage II and III gastric adenocarcinoma (including patients with AEG type III).
  • Metastatic AEG (M1b) should be treated with palliative chemotherapy (in good performance patients) or supportive care (poor performance) in asymptomatic patients.
  • Radiation therapy and endoscopic stent placement (expandable wire mesh) can be used to palliate dysphagia in patients with M1b disease.
  • [MeSH-major] Adenocarcinoma / therapy. Esophageal Neoplasms / therapy. Esophagogastric Junction / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Esophagectomy. Humans. Neoplasm Staging. Radiotherapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1999 Mar 25;340(12):908-14 [10089184.001]
  • [Cites] N Engl J Med. 1996 Aug 15;335(7):462-7 [8672151.001]
  • [Cites] Clin Radiol. 1995 Jan;50(1):11-4 [7530613.001]
  • [Cites] Lancet. 1996 Apr 13;347(9007):995-9 [8606613.001]
  • [Cites] Radiology. 1996 Jun;199(3):648-52 [8637981.001]
  • [Cites] Surgery. 1999 Feb;125(2):142-7 [10026746.001]
  • [Cites] Am J Surg. 1995 Jun;169(6):609-14 [7771626.001]
  • [Cites] J Thorac Cardiovasc Surg. 1993 Nov;106(5):860-6; discussion 866-7 [8231208.001]
  • [Cites] N Engl J Med. 1997 Jul 17;337(3):161-7 [9219702.001]
  • [Cites] J Thorac Cardiovasc Surg. 2000 Jun;119(6):1126-32 [10838528.001]
  • [Cites] World J Surg. 1992 Nov-Dec;16(6):1104-9; discussion 1110 [1455880.001]
  • [Cites] Cancer. 1994 Apr 1;73(7):1779-84 [8137201.001]
  • [Cites] Br J Cancer. 1999 Mar;79(9-10):1522-30 [10188901.001]
  • [Cites] Cancer Res. 1988 Jul 1;48(13):3843-8 [3378219.001]
  • [Cites] Arch Surg. 1996 Aug;131(8):819-24; discussion 824-5 [8712904.001]
  • [Cites] Surgery. 1997 Mar;121(3):278-86 [9092128.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Jul;17(1):49-54 [2745207.001]
  • [Cites] Eur J Cancer Prev. 1992 Apr;1(3):265-9 [1467772.001]
  • [Cites] Lancet. 1995 Mar 25;345(8952):745-8 [7891484.001]
  • [Cites] Gastrointest Endosc. 1995 Dec;42(6):507-12 [8674919.001]
  • [Cites] J Thorac Cardiovasc Surg. 1994 Nov;108(5):813-21; discussion 821-2 [7967662.001]
  • [Cites] J Clin Oncol. 1994 Feb;12(2):417-22 [8113850.001]
  • [Cites] Br J Surg. 1995 Dec;82(12 ):1678-81 [8548240.001]
  • [Cites] Ann Thorac Surg. 1997 Sep;64(3):757-64 [9307470.001]
  • [Cites] N Engl J Med. 1992 Jun 11;326(24):1593-8 [1584260.001]
  • [Cites] Br J Surg. 1988 Aug;75(8):760-3 [3167523.001]
  • [Cites] Ann Thorac Surg. 1997 Sep;64(3):752-6 [9307469.001]
  • [Cites] J Clin Oncol. 1993 Aug;11(8):1441-7 [8336183.001]
  • [Cites] Br J Cancer. 1985 Mar;51(3):399-405 [3970816.001]
  • [Cites] JAMA. 1991 Mar 13;265(10):1287-9 [1995976.001]
  • [Cites] N Engl J Med. 1999 Mar 18;340(11):825-31 [10080844.001]
  • [Cites] Semin Surg Oncol. 1999 Sep;17 (2):125-31 [10449684.001]
  • [Cites] Cancer. 1961 Mar-Apr;14:389-413 [13786981.001]
  • [Cites] J Natl Cancer Inst. 1981 Aug;67(2):243-51 [6943364.001]
  • [Cites] Gastroenterology. 1993 Feb;104(2):510-3 [8425693.001]
  • [Cites] Cancer Res. 1992 Apr 1;52(7 Suppl):2119s-2123s [1544150.001]
  • [Cites] Gastrointest Endosc. 1998 Aug;48(2):172-9 [9717783.001]
  • [Cites] N Engl J Med. 1998 Dec 31;339(27):1979-84 [9869669.001]
  • [Cites] Gastrointest Endosc. 1996 Mar;43(3):196-203 [8857133.001]
  • [Cites] Int J Cancer. 1985 May 15;35(5):593-7 [3997280.001]
  • [Cites] J Natl Cancer Inst. 1993 Sep 15;85(18):1483-92 [8360931.001]
  • (PMID = 12057146.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 47
  •  go-up   go-down


22. Kolh P, Honore P, Degauque C, Gielen J, Gerard P, Jacquet N: Early stage results after oesophageal resection for malignancy - colon interposition vs. gastric pull-up. Eur J Cardiothorac Surg; 2000 Sep;18(3):293-300
ORBi (University of Liege). Free full Text at ORBi .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: The aims of our study were to determine if using the colon as a digestive transplant after oesophagectomy for cancer was associated with increased postoperative complications, and to assess the impact of preoperative radiochemotherapy on postoperative hospital outcome.
  • Indications were squamous cell carcinoma in 69 patients and adenocarcinoma in 61.
  • There were 84 subtotal oesophagectomies, with anastomosis in the neck in 44 patients and at the thoracic inlet in 40, and 46 distal oesophageal resections.
  • The incidence of postoperative pulmonary complications was 70% (21/30 patients) in the subgroup who received preoperative radiochemotherapy, as compared to 11% (5/44 patients) in the subgroup of comparable staging, but without preoperative treatment (P<0.001).
  • Our results suggest that preoperative neoadjuvant treatment significantly increases postoperative pulmonary complications.
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma, Squamous Cell / surgery. Colon / transplantation. Esophageal Neoplasms / surgery. Esophagus / surgery. Stomach / surgery
  • [MeSH-minor] Anastomosis, Surgical / methods. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Esophagectomy. Female. Hospital Mortality. Humans. Male. Middle Aged. Palliative Care. Reoperation. Retrospective Studies. Stomach Neoplasms / drug therapy. Stomach Neoplasms / mortality. Stomach Neoplasms / radiotherapy. Stomach Neoplasms / surgery. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10973538.001).
  • [ISSN] 1010-7940
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] ENGLAND
  •  go-up   go-down






Advertisement